JP7641968B2 - Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド - Google Patents

Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド Download PDF

Info

Publication number
JP7641968B2
JP7641968B2 JP2022534664A JP2022534664A JP7641968B2 JP 7641968 B2 JP7641968 B2 JP 7641968B2 JP 2022534664 A JP2022534664 A JP 2022534664A JP 2022534664 A JP2022534664 A JP 2022534664A JP 7641968 B2 JP7641968 B2 JP 7641968B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
isvd
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504914A5 (cg-RX-API-DMAC7.html
JP2023504914A (ja
Inventor
ハイディ・ロメラエレ
アン・ブリジュ
ジーグリット・コルネリス
ブルーノ・ドンブレヒト
エリク・ローレン
メラニー・リーガー
ティモシー・スース
ジョン・パーク
ベルント・ヴァイクレ
クラウス・エルプ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2023504914A publication Critical patent/JP2023504914A/ja
Publication of JP2023504914A5 publication Critical patent/JP2023504914A5/ja
Priority to JP2025025563A priority Critical patent/JP2025081540A/ja
Application granted granted Critical
Publication of JP7641968B2 publication Critical patent/JP7641968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2022534664A 2019-12-09 2020-12-09 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド Active JP7641968B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025025563A JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945391P 2019-12-09 2019-12-09
US62/945,391 2019-12-09
EP20305064 2020-01-27
EP20305064.6 2020-01-27
PCT/EP2020/085304 WO2021116182A1 (en) 2019-12-09 2020-12-09 Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025025563A Division JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Publications (3)

Publication Number Publication Date
JP2023504914A JP2023504914A (ja) 2023-02-07
JP2023504914A5 JP2023504914A5 (cg-RX-API-DMAC7.html) 2023-10-17
JP7641968B2 true JP7641968B2 (ja) 2025-03-07

Family

ID=73793214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022534664A Active JP7641968B2 (ja) 2019-12-09 2020-12-09 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
JP2025025563A Pending JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025025563A Pending JP2025081540A (ja) 2019-12-09 2025-02-20 Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Country Status (14)

Country Link
US (5) US20210188965A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072674A1 (cg-RX-API-DMAC7.html)
JP (2) JP7641968B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984686B1 (cg-RX-API-DMAC7.html)
CN (1) CN114980974A (cg-RX-API-DMAC7.html)
AU (1) AU2020400938A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022010223A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163910A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008813A2 (cg-RX-API-DMAC7.html)
IL (1) IL293548A (cg-RX-API-DMAC7.html)
MX (1) MX2022007035A (cg-RX-API-DMAC7.html)
MY (1) MY208649A (cg-RX-API-DMAC7.html)
TW (2) TWI861302B (cg-RX-API-DMAC7.html)
WO (1) WO2021116182A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081540A (ja) * 2019-12-09 2025-05-27 アブリンクス エン.ヴェー. Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2022063984A1 (en) * 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
CA3217029A1 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
KR20250025381A (ko) 2022-06-17 2025-02-21 아포지 바이오로직스, 인크. 인터류킨 13에 결합하는 항체 및 사용 방법
WO2024017915A1 (en) * 2022-07-18 2024-01-25 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
CN118005784A (zh) 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
AU2024247861A1 (en) 2023-03-24 2025-11-06 Sanofi Asthma treatment by blocking il-13 and tslp
EP4435005A1 (en) 2023-03-24 2024-09-25 Sanofi Asthma treatment by blocking il-13 and tslp
EP4731663A2 (en) * 2023-06-22 2026-04-29 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
AR134101A1 (es) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd Anticuerpos anti-tslp y usos de los mismos
WO2025209486A1 (en) * 2024-04-02 2025-10-09 Keymed Biosciences (Chengdu) Co., Ltd. Antibodies targeting il-13 and tslp and uses thereof
WO2026041740A1 (en) 2024-08-21 2026-02-26 Sanofi Treatment of high-risk asthma by blocking il-13 and tslp
WO2026055143A2 (en) * 2024-09-03 2026-03-12 Attovia Therapeutics, Inc. Il13-binding polypeptides and uses thereof
WO2026067440A1 (zh) * 2024-09-29 2026-04-02 四川科伦博泰生物医药股份有限公司 Tslp/il-13双特异性抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン.ヴェー. 半減期の長い血清アルブミン結合タンパク質
JP2012509658A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド Il−13に結合するリガンド
JP2019502370A (ja) 2015-11-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Pd1/ctla4結合性物質
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Cd20結合単一ドメイン抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
AR064333A1 (es) * 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CA3006398A1 (en) * 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
KR20260100427A (ko) * 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
CN114980974A (zh) 2019-12-09 2022-08-30 艾伯霖克斯公司 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン.ヴェー. 半減期の長い血清アルブミン結合タンパク質
JP2012509658A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド Il−13に結合するリガンド
JP2019502370A (ja) 2015-11-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Pd1/ctla4結合性物質
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Cd20結合単一ドメイン抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochemical and biophysical research communications,2018年,Vol.504, No.1,pp.19-24

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081540A (ja) * 2019-12-09 2025-05-27 アブリンクス エン.ヴェー. Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド

Also Published As

Publication number Publication date
US12492248B2 (en) 2025-12-09
MY208649A (en) 2025-05-22
US20220177564A1 (en) 2022-06-09
TW202136302A (zh) 2021-10-01
US20220177566A1 (en) 2022-06-09
KR102984686B1 (ko) 2026-07-01
EP4072674A1 (en) 2022-10-19
US20220177565A1 (en) 2022-06-09
CA3163910A1 (en) 2021-06-17
MX2022007035A (es) 2022-06-23
JP2023504914A (ja) 2023-02-07
US20260152549A1 (en) 2026-06-04
US20210188965A1 (en) 2021-06-24
CN114980974A (zh) 2022-08-30
KR20220123237A (ko) 2022-09-06
BR112022010223A2 (pt) 2022-09-06
WO2021116182A1 (en) 2021-06-17
TW202530257A (zh) 2025-08-01
AU2020400938A1 (en) 2022-07-28
CO2022008813A2 (es) 2022-07-19
US11840566B2 (en) 2023-12-12
IL293548A (en) 2022-08-01
US12384840B2 (en) 2025-08-12
TWI861302B (zh) 2024-11-11
JP2025081540A (ja) 2025-05-27

Similar Documents

Publication Publication Date Title
US11840566B2 (en) Methods of treating asthma with polypeptides targeting IL-13 and TSLP
US11208476B2 (en) Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
JP7817994B2 (ja) Il-13およびox40lを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
CN114981300B (zh) 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
JP7719775B2 (ja) TNFαおよびOX40Lを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
MX2007004113A (es) Antagonistas y metodos para usar los mismos.
CN116783214A (zh) 包含靶向il-13和ox40l的免疫球蛋白单可变结构域的多肽
RU2836310C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на il-13 и tslp
BR122024023752A2 (pt) Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que se ligam a il-13 e/ou tslp, método de produção e usos dos mesmos, ácido nucleico, composição e uso da mesma, e hospedeiro ou célula hospedeira

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250225

R150 Certificate of patent or registration of utility model

Ref document number: 7641968

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150